(Q33490747)

27 July 2017

title

Phase II trial of fotemustine in patients with metastatic malignant melanoma (English)

1 reference

27 July 2017

main subject

phase II clinical trial

0 references

author name string

Falkson CI

series ordinal

1

1 reference

27 July 2017

Falkson G

series ordinal

2

1 reference

27 July 2017

Falkson HC

series ordinal

3

1 reference

27 July 2017

publication date

1 January 1994

1 reference

Investigational New Drugs

27 July 2017

published in

1 reference

27 July 2017

volume

12

1 reference

27 July 2017

issue

3

1 reference

27 July 2017

page(s)

251-254

1 reference

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.

27 July 2017

cites work

1 reference

12 December 2020

Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule

1 reference

12 December 2020

Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

1 reference

12 December 2020

DTIC therapy in metastatic malignant melanoma: a simplified dose schedule

1 reference

12 December 2020

Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873967

1 reference

Dimensions Publication ID

27 July 2017

1011536322

0 references

1 reference